Company Performance Drug Sales Market Performance Drug Development Drug Approval Drug Approvals Earnings Reports Biotechnology Market Analysis Eli Lilly Pfizer Product Launches Market Trends Moderna Torrent Pharmaceuticals AstraZeneca Market Competition Regulatory Affairs Clinical Trials Revenue Growth Generic Drugs Vaccines Indian Pharma Sector Sales Performance Drug Companies Drug Pricing Product Performance Vaccine Development Lupin Sales Growth Merck COVID-19 Vaccines Drug Manufacturing Corporate Earnings Sales Analysis Partnerships Dermatology Mergers and Acquisitions Regulatory Approvals R&D Expenses COVID-19 Treatments Revenue Exports Clinical Development Drug Launches Vaccine Sales Bristol Myers Squibb Production Expansion Axsome Therapeutics Innovative Drugs Corporate Performance Weight-Loss Drugs Drug Funding Market Reactions Healthcare Peer Comparison Pharmaceutical Companies Oncology Chinese Drug Makers Drug Acquisition Manufacturing Sales Trends Strategic Planning Public Companies Product Management Regulatory Compliance Sai Life Sciences Company Acquisitions Weight Loss Drugs Corporate Finance Weight-loss Drugs Online Pharmacies Weight Loss Sanofi Competitors Drug Market Generic Medicines Tariffs FDA Regulations Medications Market Dynamics Licensing Agreements Health Earnings Opioid Crisis Profitability Global Sales Merck & Co.
A one-time deal cost turned a strong sales quarter into a loss.
